Rucaparib: A New Lease of Life for Ovarian Cancer Patients

High grade epithelial ovarian cancer, along with fallopian tube and primary peritoneal cancers are generally responsive (partially or completely) to platinum based chemotherapy [1]. Significant scientific evidence has proven Rucaparib to be of substantial promise as monotherapy for maintenance of ovarian cancer patients regardless of genetic mutation [2].